Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock
Edgewise Therapeutics CEO Kevin Koch divested $785,042 worth of shares on August 12, 2026, primarily to satisfy tax obligations tied to Restricted Stock Units. The sold shares, totaling 17,971 units, were priced between $43.26 and $44.33 each. The company emphasized these were not discretionary sales by Koch. Following the sale, Koch also acquired an equal number of shares through RSU vesting, bringing his overall net change to zero.
Furthermore, Koch holds 100,000 RSUs and 200,000 stock options, with the RSUs scheduled for vesting over four years and the options monthly over the same period. Edgewise Therapeutics recently sold its muscular dystrophy business, including drug sevasemten, to Servier for up to $2.65 billion, including an upfront payment. Analysts have updated their outlook, with Oppenheimer, Guggenheim, and RBC Capital issuing positive recommendations and price targets ranging from $51 to $59.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
